Camzyos

Active substance

Mavacamten

Holder

Bristol Myers Squibb SA/NV

Status

running

Indication

The treatment of symptomatic (New York Heart Association, NYHA, class II III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients.

Public documents

Approbation

Information for the patient

Informed consent

Last update

07/11/2023